Literature DB >> 1381340

Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas.

W Wajjwalku1, S Nakamura, Y Hasegawa, K Miyazaki, Y Satoh, H Funahashi, M Matsuyama, M Takahashi.   

Abstract

We investigated the frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid tumors. DNAs from 38 thyroid papillary carcinomas and 14 follicular adenomas were analyzed by Southern blotting. Rearrangements of the ret and trk proto-oncogenes were detected in one and two papillary carcinomas, respectively, but not in follicular adenomas. Analysis by a reverse transcriptase-polymerase chain reaction method showed that the ret rearrangement-positive tumor contained the PTC/retTPC chimeric transcript, which was reported to be found specifically in thyroid tumors and adenomatous goiter. We also found that rearranged mRNA of the trk proto-oncogene was expressed at high levels in one of two trk rearrangement-positive tumors. Our results indicated that the frequency of rearrangements of these proto-oncogenes in Japanese papillary carcinomas was much lower than that in Italian patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381340      PMCID: PMC5918939          DOI: 10.1111/j.1349-7006.1992.tb01963.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  16 in total

1.  ret transforming gene encodes a fusion protein homologous to tyrosine kinases.

Authors:  M Takahashi; G M Cooper
Journal:  Mol Cell Biol       Date:  1987-04       Impact factor: 4.272

2.  Activation of a novel human transforming gene, ret, by DNA rearrangement.

Authors:  M Takahashi; J Ritz; G M Cooper
Journal:  Cell       Date:  1985-09       Impact factor: 41.582

3.  cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line.

Authors:  Y Ishizaka; T Ushijima; T Sugimura; M Nagao
Journal:  Biochem Biophys Res Commun       Date:  1990-04-30       Impact factor: 3.575

4.  A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.

Authors:  D Martin-Zanca; S H Hughes; M Barbacid
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

5.  Human TRK proto-oncogene maps to chromosome 1q32-q41.

Authors:  M Miozzo; M A Pierotti; G Sozzi; P Radice; I Bongarzone; N K Spurr; G Della Porta
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

6.  Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method.

Authors:  Y Ishizaka; S Kobayashi; T Ushijima; S Hirohashi; T Sugimura; M Nagao
Journal:  Oncogene       Date:  1991-09       Impact factor: 9.867

7.  High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.

Authors:  I Bongarzone; M A Pierotti; N Monzini; P Mondellini; G Manenti; R Donghi; S Pilotti; M Grieco; M Santoro; A Fusco
Journal:  Oncogene       Date:  1989-12       Impact factor: 9.867

8.  Involvement of the bcl-2 gene in human follicular lymphoma.

Authors:  Y Tsujimoto; J Cossman; E Jaffe; C M Croce
Journal:  Science       Date:  1985-06-21       Impact factor: 47.728

Review 9.  Translocations among antibody genes in human cancer.

Authors:  P Leder; J Battey; G Lenoir; C Moulding; W Murphy; H Potter; T Stewart; R Taub
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

10.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

Authors:  J B Konopka; S M Watanabe; O N Witte
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

View more
  22 in total

Review 1.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

2.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

Review 3.  Molecular analysis of thyroid tumors.

Authors:  Feriyl Bhaijee; Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2011-09       Impact factor: 3.943

4.  RET/PTC Gene Rearrangements in Thyroid Carcinogenesis: Assessment and Clinico-Pathological Correlations.

Authors:  Mosin S Khan; Qurteeba Qadri; Mudasir J Makhdoomi; Muneer A Wani; Aejaz A Malik; Madiha Niyaz; Shariq R Masoodi; Khurshid I Andrabi; Rauf Ahmad; Syed Mudassar
Journal:  Pathol Oncol Res       Date:  2018-11-22       Impact factor: 3.201

5.  High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.

Authors:  I Martínez; A Mantilla; M E Medrano; R Hernández; D M Hernández; M Lazos; H Santiago; B González; A Hidalgo; M Salcedo
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

6.  Low frequency of rearrangement of TRK protooncogene in Chinese thyroid tumors.

Authors:  C S Kuo; C Y Lin; C W Hsu; C H Lee; H D Lin
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

Review 7.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

8.  RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.

Authors:  Eunah Shin; Woung Youn Chung; Woo Ick Yang; Cheong Soo Park; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 9.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.

Authors:  Ken-ichi Nibu; Naoki Otsuki; Kazunari Nakao; Masashi Sugasawa; Jay L Rothstein
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-09-11       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.